Safety and Durability in Therapies for Retinal Vascular Diseases

In “Safety and Durability in Therapies for Retinal Vascular Diseases,” our panel explores how retina specialists evaluate and manage the safety profile of next-generation anti-VEGF therapies while balancing the need for greater durability and reduced treatment burden. The panelists discuss how concerns surrounding intraocular pressure (IOP), glaucoma risk, ocular hypertension, and injection volume are assessed in both clinical trials and real-world practice for patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

The expert faculty review safety findings from pivotal Phase III clinical trials evaluating newer anti-VEGF therapies, including aflibercept 8 mg, and discuss how these data have influenced clinical confidence in extending treatment intervals without introducing new safety concerns. The panel explains that despite the increased injection volume associated with higher-dose formulations, clinicians have not observed persistent elevations in intraocular pressure or additional glaucoma risk requiring changes in routine clinical monitoring or patient management.

Throughout the discussion, the panel highlights the importance of maintaining the strong safety expectations established by earlier-generation anti-VEGF therapies while advancing treatment durability and reducing injection frequency. The expert faculty also discuss how extended treatment intervals may help decrease clinic burden and improve the patient experience without adding additional safety-related monitoring requirements. The conversation emphasizes how maintaining a favorable safety profile alongside improved durability may help optimize long-term real-world outcomes for patients living with retinal vascular diseases.

Our next episode, “Long-term Management in Retinal Vascular Diseases,” features the panelists discussing how extended dosing intervals and reduced injection burden may improve patient adherence and long-term disease control in AMD, DME, and RVO. The expert faculty also highlight how next-generation anti-VEGF therapies may help optimize real-world outcomes through greater treatment durability and persistence.